The CRISPR/Cas9 system is widely used to generate gene-edited animals. Here, we developed an efficient system for generating genetically modified mice using maternal Cas9 from Cas9 transgenic mice. Using this system, we achieved lower mosaicism and higher rates of knock-in success, geneediting, and birth compared to the similar parameters obtained using exogenously administered Cas9 (mRNA/protein) system. Furthermore, we successfully induced simultaneous mutations at multiple loci (a maximum of nine). Our novel gene-editing system based on maternal Cas9 could potentially facilitate the generation of mice with single and multiple gene modifications. Genetically modified (GM) organisms, with specific genes altered (added or ablated), are widely used for modeling human and animal diseases. They are particularly useful for understanding the molecular mechanisms of diseases and for the development of novel disease treatments 1,2. In the past three decades, GM animals have been created by microinjecting transgenes into zygote nuclei (zygote microinjection) or by injecting the blastocoel with GM embryonic stem cells engineered to exhibit altered expression of a specific gene by gene targeting technology 3,4. It is now easier than ever to create GM animals by using the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated-9 (CRISPR/Cas9) genome editing system 5-12 due to its wide applicability, high efficiency, and design simplicity 13-15. The most commonly used approach for generating GM animals with the CRISPR/Cas9 system is by microinjecting the CRISPR/Cas9 components, such as Cas9 DNA, mRNA or protein, guide RNA (gRNA), and, in some cases, a homology direct repair (HDR) template, into the zygote 16-20. gRNA efficiently induces Cas9-mediated double strand breaks at desired target sites, which stimulate DNA repair by at least two distinct mechanisms: non-homologous end joining and HDR 21-23. However, the zygote microinjection-based genome editing system has inherent problems. For example, frequent mosaicism for inducing insertion/deletion (indel) at the target locus is seen in almost all individuals obtained using this approach 24-26. Given that transcription and translation are suppressed in mouse zygotes, the translation of the introduced Cas9 DNA/mRNA into its active enzymatic form is likely delayed until after the first cell division, causing unequal genome editing in individual blastomeres 27. It has been recently reported that direct Cas9 protein expression in early-stage mouse zygotes reduces the occurrence of mosaic mutations 28. In addition, the amount of CRISPR/ Cas9 reagents injected into the zygote is limited as high volumes are often associated with developmental arrest of the embryos 29 , reducing the possibility of simultaneous modifications in multiple genes using the CRISPR/Cas9 system 11. Previously, we tackled these problems by generating systemically Cas9-expressing transgenic (Tg) (sCAT) mice that produce maternal Cas9 (maCas9), which exhibits nuclease activity, during...